Progenics Pharmaceuticals Inc $4.95

down -0.08


31/7/2014 09:35 AM  |  NASDAQ : PGNX  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get PGNX Trend Analysis - it has underperformed the S&P 500 by 34%

Partner Headlines

  1. Morning Market Movers

    Benzinga
  2. Benzinga's Top #PreMarket Gainers

    Benzinga
  3. US Stock Futures Surge; All Eyes On Citigroup Results

    Benzinga
  4. UPDATE: Salix, Progenics Report FDA Office Of Drug Evaluation III Approves ...

    Benzinga
  5. Progenics Announces Will Host Call Related to FDA Appeal Response Related ...

    Benzinga
  6. Progenics, Nektar Still Halted; FDA Advisory Committee Expected To Conclude ...

    Benzinga
  7. Small Pharmaceuticals Rallying Following FDA Report

    Benzinga
  8. Mid-Afternoon Market Update; Hertz Down, QuikSilver Gain On CEO & CFO Share ...

    Benzinga
  9. Mid-Day Market Update: Diamond Foods Shares Fall After Weak Earnings; GW ...

    Benzinga
  10. Earnings Scheduled For May 9, 2014

    Benzinga
  11. Progenics Pharmaceuticals Announces Completion of Enrollment of Chemotherapy ...

    Benzinga
  12. US Stock Futures Edge Higher Ahead Of McDonald's Earnings

    Benzinga
  13. Salix Pharmaceuticals, Progenics Pharmaceuticals Announce the Acceptance ...

    Benzinga
  14. Earnings Scheduled For March 13, 2014

    Benzinga
  15. 2 Deaths, 25% Plunge -- And Still A Big Upside

    YCharts
  16. Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, ...

    Benzinga
  17. Progenics Pharmaceuticals Relaunches Registrational Trial of Azedra to ...

    Benzinga
  18. Earnings Scheduled For November 11, 2013

    Benzinga
  19. Salix Pharmaceuticals Thrives With Promising GI Drugs

    IBD
  20. Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX

    GuruFocus
  21. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 1,215 ...

    GuruFocus
  22. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 1,142 ...

    GuruFocus
  23. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 1,607 ...

    GuruFocus
  24. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 11,8 ...

    GuruFocus
  25. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 49,793 ...

    GuruFocus
  26. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 48,833 ...

    GuruFocus
  27. Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  28. Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Robert Baker buys 1,162 ...

    GuruFocus
  29. Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX

    GuruFocus
  30. Progenics Pharmaceuticals Inc. (PGNX) CEO Mark Robert Baker buys 1,036 ...

    GuruFocus
  31. 5 Stocks That Dropped the Most Since Gurus Bought Them

    GuruFocus
  32. EZchip Semiconductor, Sagent Pharmaceuticals Among Stocks setting 52-Week ...

    FoxBusiness
  33. Salix trounces Q2 estimates

    IBD
  34. Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  35. Salix Pharmaceuticals Beats, Announces Licensing Deal

    IBD
  36. ProShares Trust Ultra VIX Short Term Futures ETF, Direxion Daily Large ...

    FoxBusiness
  37. Stocks Finish Little Changed Ahead of Central Bank Meetings with Coca-cola ...

    MarketIntelligenceCenter
  38. Salix, Progenics Stocks Fall On Drug Approval Delay

    IBD
  39. Stock Futures Mixed; Salix, Progenics Tumble

    IBD
  40. Benzinga's Top Pre-Market Losers

    Benzinga
  41. Financial Breakfast: Morning News Summary for July 30, 2012

    Benzinga
  42. Salix Q1 Results Beat Estimates; Raises EPS Guidance

    IBD
  43. Microcap Movers for Tuesday December 20, 2011

    Benzinga
  44. Stocks Bounce Back In Big Volume

    IBD
  45. Progenics Pharma Up 30% on Positive Phase 3 Results

    Benzinga
  46. Notable Call Options Activity in Progenics Pharmaceuticals

    Benzinga
  47. Morning Market Movers

    Benzinga
  48. Progenics Pharmaceuticals Lures Call Players in the Options Pits

    SchaeffersResearch
  49. Notable Call Options Activity in Progenics Pharmaceuticals

    Benzinga
Trading Center